MedPath

The Anabolic Properties of a Lipid-rich Pork Matrix

Not Applicable
Recruiting
Conditions
Muscle Protein Synthesis
Interventions
Other: 95.1% Lean Pork
Other: Carbohydrate Beverage
Other: 81.16% Lean Pork
Registration Number
NCT05876299
Lead Sponsor
University of Illinois at Urbana-Champaign
Brief Summary

The amount and quality of skeletal muscle mass determines physical performance, but also a significant contributor to metabolic health. As such, the maintenance of skeletal muscle mass is relevant across the lifespan to remain active in family and community life. Food ingestion, particularly protein, is one of the main anabolic to skeletal muscle tissue by stimulating muscle protein synthesis rates. There have been multiple attempts to identify specialized performance nutrition products (e.g., various isolated protein powders) to maximize the anabolic properties of dietary protein on muscle. Our research group, however, has advocated for a food focus approach to meet dietary protein requirements. Particularly, we propose that whole foods demonstrate food matrix effects (nutrient-nutrient interactions) that creates a greater anabolic action on muscle beyond what amino acids can create alone. Therefore, the objective of this study is to identify the anabolic properties of consuming lipid-rich pork products when compared to their leaner counter-parts. Our working hypothesis that the ingestion of 84% or 96% lean ground pork condition will stimulate a greater increase in muscle protein synthesis rates compared to an isocaloric carbohydrate beverage in healthy adults. We further hypothesize that the ingestion of 84% lean pork will augment the stimulation of muscle protein synthesis rates to a greater extent than 96% lean ground pork. To achieve our objective, we will recruit 15 healthy men and women (20-50 y) to receive prime-constant infusions to directly measure muscle protein synthesis rates before and after treatment ingestion using our lab's established methods.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Age 20-50 yrs
  • Pre-menopausal
  • Recreationally active
  • Weight stable for prior 6 months
Exclusion Criteria
  • Age outside of range (20 - 50 yrs)
  • Pregnancy
  • Irregular menstrual cycles
  • Participation in previous research using [13C6]phenylalanine
  • Participation in other ongoing research that interferes with this study (e.g., conflicting diet, activity interventions, etc.)
  • Any hospitalization or surgery for a metabolic, cardiovascular, or neuromusculoskeletal complication within the past year
  • Allergy or hypersensitivity to local anesthetics, latex, or adhesives (bandages, medical tape, etc.)
  • Excess scarring after injury
  • History of excess bleeding after cut
  • Chronic or frequent dizziness/fainting, and arm or leg weakness/numbness
  • Arthritis
  • Tumors
  • Mental Illness
  • Hepatorenal, cardiovascular musculoskeletal, autoimmune, or neurological disease or disorder
  • Predisposition to hypertrophic scarring or keloid formation
  • Physical activity limitations
  • Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation
  • Consumption of thyroid, androgenic, or other medications known to affect endocrine function
  • Consumption of medications known to affect protein metabolism (e.g., prescription-strength corticosteroids, non-steroidal anti-inflammatories, or acne medication)
  • Unwillingness to comply with study procedures
  • Weight unstable (variation >5% of bodyweight in last 6-12 months)
  • Current or previous tobacco use with last 6 months
  • Obesity (body mass index; BMI > 30 kg/m^2)
  • Score of less than 14 or greater than 24 on Godin-Shephard Leisure-Time Physical Activity Questionnaire
  • Phenylketonuria
  • Anyone hospitalized previously for COVID-19 without a cardiovascular workup screening for cardiovascular issues post-infection
  • Anyone recovering from COVID-19 infection within the preceding 10 days

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Low-Fat Pork95.1% Lean PorkThis condition will consist of consuming 90.2 g of low-fat (4.90% crude fat) ground pork.
Carbohydrate ControlCarbohydrate BeverageThis condition will consist of a carbohydrate beverage.
High-Fat Pork81.16% Lean PorkThis condition will consist of consuming 109.6 g of high-fat (18.84% crude fat) ground pork.
Primary Outcome Measures
NameTimeMethod
Myofibrillar Fractional Synthetic RateDuring 5-hour post-prandial period following consumption of the study meal or beverage

Rate of building new protein in skeletal muscle contractile protein

Secondary Outcome Measures
NameTimeMethod
Plasma Amino Acid ConcentrationDuring the 3-hour post-absorptive period prior to ingestion of the study meal or beverage and throughout the 5-hour post-prandial period following meal ingestion

Concentration of amino acids in plasma as determined by LC/MS/MS

Plasma Free Fatty Acid ConcentrationDuring the 3-hour post-absorptive period prior to ingestion of the study meal or beverage and throughout the 5-hour post-prandial period following meal ingestion

Concentration of amino acids in plasma as determined by GC-MS

Plasma Insulin ConcentrationDuring the 3-hour post-absorptive period prior to ingestion of the study meal or beverage and throughout the 5-hour post-prandial period following meal ingestion

Concentration of insulin in plasma as determined by commercially-available ELISA kits

Plasma Glucose ConcentrationDuring the 3-hour post-absorptive period prior to ingestion of the study meal or beverage and throughout the 5-hour post-prandial period following meal ingestion

Concentration of glucose in plasma as determined by an automated biochemistry analyzer (YSI)

Trial Locations

Locations (1)

Louise Freer Hall (University of Illinois Urbana-Champaign)

🇺🇸

Urbana, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath